MSK Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
*[[Media:2022-04-26_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|April 26, 2022]] | |||
*[[Media:2022-03-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|March 22, 2022]] | *[[Media:2022-03-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|March 22, 2022]] | ||
*[[Media:2022-02-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|February 22, 2022]] | *[[Media:2022-02-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|February 22, 2022]] | ||
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
Revision as of 17:05, 24 May 2022
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Profile Documents
- MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile
- MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile